TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02765412

Intervention type: OTHER
Intervention: LEAP
Description: Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).

Intervention type: OTHER
Intervention: Audit and Feedback
Description: Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).

Intervention type: OTHER
Intervention: Audit and Feedback
Description: Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).

Intervention type: OTHER
Intervention: Academic Detailing
Description: All sites will be offered an academic detailing approach to implementation of Lung Decision Precision. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.

Intervention type: OTHER
Intervention: Academic Detailing
Description: All sites will be offered an academic detailing approach to implementation of Lung Decision Precision. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.
Study: NCT03239119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rE-4 5 mcg
Description: Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rE-4 10 mcg
Description: Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 5 mcg
Description: Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10 mcg
Description: Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily
Study: NCT02184793

Intervention type: DEVICE
Group type: OTHER
Intervention: EMD (Inclinomax)
Description: EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on

Intervention type: DEVICE
Group type: OTHER
Intervention: EMD (Inclinomax)
Description: EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
Study: NCT04171466

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin + Metronidazole
Description: Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin + Metronidazole
Description: Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SH-DS01
Description: SH-DS01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SH-DS01
Description: SH-DS01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for SH-DS01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for SH-DS01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
Study: NCT01039701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: capsules, oral, 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: capsules, oral, 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: capsules, oral, 3 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, oral, 3 times daily, 4 weeks
Study: NCT01859481

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan HBr 40 mg
Description: All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan HBr 80 mg
Description: All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
Study: NCT00003298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: The surgical procedure performed involved a radical subtotal or total gastrectomy.~A complete surgical resection was required

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
Study: NCT00514735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medtronic Cardiac Ablation System
Description: Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Class I or III Antiarrhythmic Medications
Description: Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
Study: NCT00335322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)
Description: Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
Description: Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
Description: Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
Study: NCT03756103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet Dose 1
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet Dose 2
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet Dose 3
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPH3127 tablet Placebo
Description: Oral SPH3127 tablet placebo, once daily for 8 weeks.
Study: NCT01570829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietressa
Description: Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study: NCT03588026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVA576
Description: 6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVA576
Description: 6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC)
Description: 6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC)
Description: 6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
Study: NCT01475968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrafine Air Pollution Particulate Matter
Description: Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Filtered Air
Description: Filtered Air
Study: NCT02636634

Intervention type: OTHER
Group type: OTHER
Intervention: imaging
Study: NCT03238027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
Study: NCT00796484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL888
Description: Administered orally
Study: NCT03522584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypofractionated Image-Guided Radiation Therapy
Description: Undergo HIGRT
Study: NCT02165228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: Stress reduction class and behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Enhancement
Description: Nutrition education class and behavioral intervention
Study: NCT02916381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEC block + General anaesthesia
Description: Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
Study: NCT01019694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combivent CFC-MDI
Description: 36/206 mcg Four times a day (QID)
Study: NCT02829853

Intervention type: GENETIC
Intervention: Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING
Description: Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo \& HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.

Intervention type: GENETIC
Intervention: Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING
Description: Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo \& HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
Study: NCT02089880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-brace
Description: The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-brace
Description: The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stance control orthosis
Description: The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stance control orthosis
Description: The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
Study: NCT00362518

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Study Arm A
Description: Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study Arm B
Description: This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study Arm C
Description: This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study Arm D
Description: This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
Study: NCT00003532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01290432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inofolic Plus
Description: Inofolic Plus contains folic acid and myoinositol and melatonin
Study: NCT01019694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent Respimat 20/100 mcg
Description: Open label randomized parallel
Study: NCT02270333

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham inspiratory muscle training
Description: Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Study: NCT00528138

Intervention type: OTHER
Intervention: Laboratory Test
Description: CRP, white blood cell count, hepatic function tests

Intervention type: OTHER
Intervention: Laboratory Test
Description: CRP, white blood cell count, hepatic function tests
Study: NCT02405520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dosage HPV Vaccine
Description: Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage HPV Vaccine
Description: Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage HPV Vaccine
Description: Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aluminium Adjuvant
Description: Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
Study: NCT03632382

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D acquisition of maxillofacial characteristics
Description: A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
Study: NCT01953848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral